Schulze, S.; Jotschke, S.; Engelmann, R.; Ludwig-Kraus, B.; Kraus, F.B.; Jaekel, N.; Zahn, C.; Junghanss, C.; Böttcher, S.; Al-Ali, H.K.
Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology. Cancers 2025, 17, 2674.
https://doi.org/10.3390/cancers17162674
AMA Style
Schulze S, Jotschke S, Engelmann R, Ludwig-Kraus B, Kraus FB, Jaekel N, Zahn C, Junghanss C, Böttcher S, Al-Ali HK.
Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology. Cancers. 2025; 17(16):2674.
https://doi.org/10.3390/cancers17162674
Chicago/Turabian Style
Schulze, Susann, Sabrina Jotschke, Robby Engelmann, Beatrice Ludwig-Kraus, Frank Bernhard Kraus, Nadja Jaekel, Christina Zahn, Christian Junghanss, Sebastian Böttcher, and Haifa Kathrin Al-Ali.
2025. "Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology" Cancers 17, no. 16: 2674.
https://doi.org/10.3390/cancers17162674
APA Style
Schulze, S., Jotschke, S., Engelmann, R., Ludwig-Kraus, B., Kraus, F. B., Jaekel, N., Zahn, C., Junghanss, C., Böttcher, S., & Al-Ali, H. K.
(2025). Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology. Cancers, 17(16), 2674.
https://doi.org/10.3390/cancers17162674
